Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 4
2001 2
2002 1
2003 2
2004 8
2005 5
2006 4
2007 7
2008 6
2009 2
2010 1
2011 3
2012 4
2013 2
2014 4
2015 5
2016 4
2017 5
2018 3
2019 9
2020 9
2021 10
2022 6
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P. Herbst RS, et al. Among authors: ceresoli gl. J Clin Oncol. 2020 May 10;38(14):1580-1590. doi: 10.1200/JCO.19.02446. Epub 2020 Feb 20. J Clin Oncol. 2020. PMID: 32078391 Free article. Clinical Trial.
PURPOSE: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) 50% and 1 …
PURPOSE: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-lig …
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Among authors: ceresoli gl. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
This regimen is a new treatment option for previously untreated advanced pleural mesothelioma. FUNDING: The Canadian Cancer Society and Merck & Co....
This regimen is a new treatment option for previously untreated advanced pleural mesothelioma. FUNDING: The Canadian Cancer Society a …
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases.
Andreano A, Valsecchi MG, Russo AG, Siena S; Lombardy Lung Cancer Working Group. Andreano A, et al. Arch Public Health. 2021 Jan 25;79(1):12. doi: 10.1186/s13690-021-00528-0. Arch Public Health. 2021. PMID: 33494836 Free PMC article.
METHODS: Thirty-four indicators were selected by revision of main guidelines by cancer epidemiologists, and then evaluated by a multidisciplinary panel of clinicians involved in lung cancer care and working on the pathway of lung cancer diagnosi …
METHODS: Thirty-four indicators were selected by revision of main guidelines by cancer epidemiologists, and then evaluated by a multi …
MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises.
Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM, Wannesson L. Cortinovis D, et al. Among authors: ceresoli gl. Curr Pharm Des. 2014;20(24):3982-90. doi: 10.2174/13816128113196660755. Curr Pharm Des. 2014. PMID: 24138721 Review.
Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes …
Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis …
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.
Di Noia V, D'Aveni A, D'Argento E, Rossi S, Ghirardelli P, Bortolotti L, Vavassori V, Bria E, Ceresoli GL. Di Noia V, et al. Among authors: ceresoli gl. ESMO Open. 2021 Dec;6(6):100280. doi: 10.1016/j.esmoop.2021.100280. Epub 2021 Oct 9. ESMO Open. 2021. PMID: 34634633 Free PMC article. Review.
A precision medicine approach has been successfully applied in medical oncology for the treatment of non-small-cell lung cancer (NSCLC) through the identification of targetable driver molecular aberrations; activating mutations of epidermal growth factor receptor (E …
A precision medicine approach has been successfully applied in medical oncology for the treatment of non-small-cell lung cancer …
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
BACKGROUND: Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. ...CONCLUSION: Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients …
BACKGROUND: Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment …
Clinical staging of malignant pleural mesothelioma: current perspectives.
Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL. Bonomi M, et al. Among authors: ceresoli gl. Lung Cancer (Auckl). 2017 Aug 18;8:127-139. doi: 10.2147/LCTT.S102113. eCollection 2017. Lung Cancer (Auckl). 2017. PMID: 28860886 Free PMC article. Review.
The recommended and recently updated classification for clinical use is the TNM staging system established by the International Mesothelioma Interest Group and the International Association for the Study of Lung Cancer, which is based mainly on surgical and patholog …
The recommended and recently updated classification for clinical use is the TNM staging system established by the International Mesothelioma …
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. Cappuzzo F, et al. Among authors: ceresoli gl. Br J Cancer. 2005 Dec 12;93(12):1334-40. doi: 10.1038/sj.bjc.6602865. Br J Cancer. 2005. PMID: 16288303 Free PMC article.
In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). ...
In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutation …
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Cappuzzo F, et al. Among authors: ceresoli gl. J Natl Cancer Inst. 2005 May 4;97(9):643-55. doi: 10.1093/jnci/dji112. J Natl Cancer Inst. 2005. PMID: 15870435 Clinical Trial.
BACKGROUND: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene …
BACKGROUND: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers …
98 results